Category: Pharma, Life Sciences & Med Tech Players
-
Jury accepts “reverse doctrine of equivalents” defense in blood pump patent case involving Johnson & Johnson unit
Abiomed and Maquet have been engaged in a long-running battle over blood pump technology.
-
Global pharma company Adalvo eying U.S. expansion, says Chief IP Officer
While the B2B pharma company has expanded its European business significantly in the last decade, it is now turning to the U.S. to bring its licensing business, Adalvo’s Toni Santamaria told ip fray at IP Dealmakers earlier this month.
-
China Implements Pharmaceutical Test Data Protection Rules: A New Era for Drug Data Protection
China has promulgated the Measures for the Implementation of Pharmaceutical Test Data Protection and the Work Scheme for Pharmaceutical Test Data Protection, which together operationalize for the first time a formal PTDP system in China, granting up to six years of data exclusivity to qualifying chemical and biological drug applicants.
-
Pharma giant Takeda ordered to pay over $884 million in damages in Amitiza class action suit: patent litigation settlement was anticompetitive, jury finds
Takeda has said it already plans to “vigorously” appeal the decision, which found its 2014 deal with competitor Par Pharmaceutical to drop its challenge to its AMITIZA patents and delay its generic entry by seven years, anticompetitive.
-
Actelion falls foul of disclosure-dedication rule, prosecution estoppel in Federal Circuit challenge to Mylan’s hypertension generic
The Federal Circuit agreed that there was neither literal infringement, nor infringement under the doctrine of equivalents.
-
CureVac expands Spikevax patent fight to UPC with new action against Moderna in Hague LD
In a significant patent battle for mRNA vaccines, CureVac has now joined others in suing in the UPC, taking the dispute with Moderna, which started in Delaware, to the Hague LD.
-
District judge opens door to rare “reverse doctrine of equivalents” defense in medical device dispute
The judge’s order came amid long-running litigation between Maquet and Abiomed in the United States District Court for the District of Massachusetts over intravascular blood pump technologies.
-
Federal Circuit analysis would create “substantial disincentive” to generic entry, USDOJ tells Supreme Court in Hikma v. Amarin
The key arguments centred on whether it was plausible that Hikma’s marketing amounted to inducement to infringe.
-
Merz wins UPC appeal as CoA overturns Paris LD denial and grants PI against Viatris generic in France
The UPC CoA has reversed the Paris LD’s refusal of interim relief and granted Merz a preliminary injunction against Viatris Santé’s fampridine generic in France.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.